CN101337000B - Solanum nigrum extract, preparation method and pharmaceutical application thereof - Google Patents
Solanum nigrum extract, preparation method and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN101337000B CN101337000B CN2008100336197A CN200810033619A CN101337000B CN 101337000 B CN101337000 B CN 101337000B CN 2008100336197 A CN2008100336197 A CN 2008100336197A CN 200810033619 A CN200810033619 A CN 200810033619A CN 101337000 B CN101337000 B CN 101337000B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- black nightshade
- resin
- extract
- mentioned steps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000002594 Solanum nigrum Nutrition 0.000 title claims abstract description 112
- 239000000284 extract Substances 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 244000061457 Solanum nigrum Species 0.000 title description 32
- 240000002307 Solanum ptychanthum Species 0.000 claims abstract description 81
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000006673 asthma Diseases 0.000 claims abstract description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 141
- 239000011347 resin Substances 0.000 claims description 42
- 229920005989 resin Polymers 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 29
- 238000010828 elution Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 26
- 239000003513 alkali Substances 0.000 claims description 23
- 239000012141 concentrate Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 15
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000003729 cation exchange resin Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000003208 petroleum Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 238000005554 pickling Methods 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005238 degreasing Methods 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 125000000524 functional group Chemical group 0.000 claims description 3
- 235000008216 herbs Nutrition 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 abstract description 21
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 abstract description 20
- KNLOWJPFLKGYGQ-UHFFFAOYSA-N Solasodine 3-O-??-L-rhamnopyranosyl (1‘Â∆2)-O-[??-D-glucopyranosyl (1‘Â∆4)]-??-D-glucopyranoside Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O KNLOWJPFLKGYGQ-UHFFFAOYSA-N 0.000 abstract description 19
- QCTMYNGDIBTNSK-UHFFFAOYSA-N Solasonin Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O QCTMYNGDIBTNSK-UHFFFAOYSA-N 0.000 abstract description 19
- QCTMYNGDIBTNSK-QCNFCIKQSA-N Solasonine Natural products O([C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@@H](C)[C@@]7(O[C@H]6C5)NC[C@H](C)CC7)CC4)CC=3)CC2)O[C@@H](CO)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QCTMYNGDIBTNSK-QCNFCIKQSA-N 0.000 abstract description 19
- RCTKRNCKOYYRIO-UHFFFAOYSA-N alpha-Solamarine Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O RCTKRNCKOYYRIO-UHFFFAOYSA-N 0.000 abstract description 19
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 abstract description 19
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 13
- SGEKLQMLYWFVFY-VAVRQHLYSA-N ac1l4bck Chemical compound O([C@@H]1[C@@H](O)[C@H](C)O[C@H]([C@@H]1O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)C[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O SGEKLQMLYWFVFY-VAVRQHLYSA-N 0.000 description 13
- 238000007920 subcutaneous administration Methods 0.000 description 13
- 239000002504 physiological saline solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000003708 ampul Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 8
- 208000014018 liver neoplasm Diseases 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000000291 postprandial effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000005341 cation exchange Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930008677 glyco alkaloid Natural products 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000207763 Solanum Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940031352 solanine Drugs 0.000 description 2
- KWVISVAMQJWJSZ-VKROHFNGSA-N solasodine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CN1 KWVISVAMQJWJSZ-VKROHFNGSA-N 0.000 description 2
- JXWLYDNHVXFBJA-UHFFFAOYSA-N solasodine Natural products CC1CCC2(NC1)NC3CC4C5CC=C6CC(O)CCC6(C)C5CCC4(C)C3C2C JXWLYDNHVXFBJA-UHFFFAOYSA-N 0.000 description 2
- 229930003352 steroid alkaloid Natural products 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 235000008406 SarachaNachtschatten Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 235000004790 Solanum aculeatissimum Nutrition 0.000 description 1
- 235000008424 Solanum demissum Nutrition 0.000 description 1
- 235000018253 Solanum ferox Nutrition 0.000 description 1
- 235000000208 Solanum incanum Nutrition 0.000 description 1
- 235000013131 Solanum macrocarpon Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 235000009869 Solanum phureja Nutrition 0.000 description 1
- 235000000341 Solanum ptychanthum Nutrition 0.000 description 1
- 235000017622 Solanum xanthocarpum Nutrition 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHZGCJCMOBCMKK-DVKNGEFBSA-N alpha-D-quinovopyranose Chemical compound C[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-DVKNGEFBSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000010437 gem Substances 0.000 description 1
- 229910001751 gemstone Inorganic materials 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a black nightshade extract, a preparation method and a pharmaceutical application thereof. Wherein the total content of the solasonine, the solamargine and the solasonine is 80-99 wt%, the content of the solasonine is 30-50 wt%, the content of the solamargine is 10-30 wt%, and the content of the solasonine is 30-50 wt%. The invention also relates to a preparation method of the black nightshade extract and application of the black nightshade extract as an active ingredient in preparing medicaments for preventing and treating diseases such as tumors, diabetes, asthma, coronary heart disease and the like.
Description
Technical field
The present invention relates to the plant black nightshade extract, its preparation method and as the application of the medicine of diseases such as active component preparation prevention and treatment tumour, diabetes, asthma, coronary heart disease.
Background technology
Black nightshade Solalum Nigrum L. is annual Solanum herbaceous plant, and all there is growth most of at home provinces and regions.The herb hyoscine, cold in nature, bitter is hot little sweet, slightly poisonous, returns lung, urinary bladder channel.The ability eliminating stasis to subdue swelling is clearing heat and detoxicating.Gold-coloured staphylococci, typhoid bacillus, shigella dysenteriae, proteus, Escherichia coli, pseudomonas aeruginosa, hog cholera bacillus all there is stronger bacteriostasis; The cancer cell of inhibition and effects such as urinary system infection contamination and leukorrhea are arranged; Treatment carbuncle commonly used is swollen; Tumour, dysentery etc., it is among the people that to be used to treat diabetes curative effect remarkable.Black nightshade also has certain dietary function in addition, therefore has good medical value.Be rich in steroid alkaloid in the plant; ((δ-solanigrine), black nightshade are decided alkali (solanigridine), solasurine solasurine etc. for ε-solanigrine), δ-solanine like: solasonine (solasonine), solamargine (solamargine), the bright alkali of Australia eggplant (solasodamine), ε-solanine; These steroid alkaloids all are present in Solanum nigrum stem, leaf, root, really with the form of glycosides, and aglycon is solasodine (solasodine).
Solasonine solasonine solamargine solamargine
Solasurine solasurine
Solasonine and solamargine are two main in black nightshade alkaloid components; In in vitro test; Two compounds all show the destructiveness of cell membrane fat; Both show cooperative effect, and the destructiveness of solamargine is stronger, and rhamnose wherein possibly play important function in the combining of guiding glycoalkaloid and cell; Some researchs to solamargine show, thus solamargine can regulate the expression of Tumor Necrosis Factor Receptors and cause cancer cell-apoptosis, 2 rhamnose possibly play a decisive role in triggering Apoptosis.Other glycoalkaloid also shows approximate physiologically active.Therefore, find out suitable technology, from black nightshade, extract glucosides TA position, carry out drug efficacy study, can be used as a direction of anti-cancer agent research.To the research of prophylactic treatment diabetes, asthma and the coronary heart disease isoreactivity of black nightshade crude extract also is external focus at present, but at present also not research show it is that which chemical composition is in action in the crude extract definitely.
Water-soluble extract, its preparation method and the pharmaceutical compositions thereof of the disclosed nightshade of Chinese patent Granted publication CN1329038C, wherein water-soluble extract is to be that solasonine and solamargine by 60%-90% constitutes basically.
The black nightshade method for distilling cost that uses at present is higher, and active constituent content is lower, and impurity is more, and the pollution that produces in the preparation process is bigger.The product content of effective that after extracting, obtains has limited its use in pharmaceutical compositions, still can not satisfy the needs of efficient pharmaceutical compositions.
Summary of the invention
The object of the invention first aspect has provided a kind of black nightshade extract.
The object of the invention second aspect provides the preparation method of above-mentioned black nightshade extract.
The object of the invention third aspect provides the application of above-mentioned black nightshade extract in medicine.
As the black nightshade extract of first aspect present invention, comprise solasonine and solamargine, also comprise solasurine, wherein solasonine, solamargine and solasurine three's total content is 80wt%～99wt%.
Solasonine content is 30wt%～50wt%, and solamargine content is 10wt%～30wt%, and solasurine content is 30wt%～50wt%.
Preparation method as the black nightshade extract of second aspect present invention may further comprise the steps:
(1) black nightshade herb and fruit add alcohol extract, collect extract A;
(2) ethanol in the recovery extract gets concentrate B to there not being the alcohol flavor;
(3) concentrate B uses cationic exchange resin adsorption, and water, ethanol and contain alkali ethanol and carry out wash-out are successively collected and contained alkali ethanol elution portion C;
(4) contain alkali ethanol elution portion C, reclaim ethanol and get concentrate D;
(5) supernatant is abandoned in concentrate D centrifugation, gets sediment E;
(6) sediment E is washed with water to near-white and supernatant pH value less than 9, promptly gets black nightshade extract after the deposition drying.
In above-mentioned steps (1), at every turn make a living 2～8 times of volumes of dose of consumption of ethanol; The weight percent concentration of ethanol is 50%～95%.Be preferably at every turn make a living 5 times of volumes of dose of consumption of ethanol; The weight percent concentration of ethanol is 90%.
In above-mentioned steps (1), adopt and reflux or the ultrasonic power extraction, extraction time is 2～5 times, each 1～3 hour.Be preferably and adopt reflux type to extract, extraction time is 3 times, each 1.5 hours.
When raw medicinal herbs is the black nightshade herb, in above-mentioned steps (2), increase by one to the step of concentrate B with the petroleum ether extraction degreasing.Be preferably concentrate B with 3 degreasings of equal-volume petroleum ether extraction.
In above-mentioned steps (3), make a living 0.5～5 times of volume of dose of the consumption of cationic ion-exchange resin.Be preferably 1 times of volume of crude drug amount.
The functional group of said cationic ion-exchange resin is a kind of among sulfonic group, pyrovinic acid base, phosphate, carboxyl and the phenolic hydroxyl group.Be preferably sulfonic group.
In above-mentioned steps (3), preferred elution process is closely colourless to flowing out liquid with washed resin for successively, and the weight percent concentration of 1～10 times of resin volume is 30%～90% ethanol elution, 0.5～10 times of resin volume contain the alkali ethanol elution.Preferred elution process is closely colourless to flowing out liquid with washed resin for successively; The weight percent concentration of 1～2 times of resin volume is 30%～60% ethanol elution; The weight percent concentration of 1～5 times of resin volume is 90% ethanol elution, 1～5 times of resin volume contain the alkali ethanol elution.Most preferred type of elution is closely colourless to flowing out liquid with washed resin for successively; The weight percent concentration of 1 times of resin volume is 40% ethanol elution; The weight percent concentration of 2 times of resin volumes is 90% ethanol elution, 3 times of resin volumes contain the alkali ethanol elution.
In above-mentioned steps (3), the said alkali ethanol that contains is that weight percent concentration is the mixed solution of 50～95% ethanol and alkali, and wherein alkali is a kind of among ammoniacal liquor, NaOH, sodium carbonate, sodium acid carbonate and other commercial production alkali commonly used.Preferably containing alkali ethanol is that weight percent concentration is that 90% ethanol is the solution that 25% ammoniacal liquor mixed in 10: 1 by volume with weight percent concentration.
In above-mentioned steps (6),, increase by a usefulness washing with acetone and be precipitated to subalbous step if sediment E color is darker.
In above-mentioned steps (3), described cationic ion-exchange resin can be regenerated, and the method for its regeneration is: add the heat soaking resin with 2% sodium hydrate aqueous solution; The dress post, the sodium hydrate aqueous solution 800ml wash-out with 2%; Water is washed till outflow liquid and is neutral; Using 1N salt pickling resin is 2 to flowing out liquid pH value; Using deionized water to wash resin is 6 to flowing out liquid pH value, can drop into repeated use.
Solasonine, solamargine and solasurine three's total content is 80wt%～99wt% in the black nightshade extract that method produced according to the present invention obtains; Solasonine content is 30wt%～50wt%; Solamargine content is 10wt%～30wt%, and solasurine content is 30wt%～50wt%.
As the medicinal usage of the above-mentioned black nightshade extract of third aspect present invention be with the solasonine in the described black nightshade extract, solamargine and solasurine as active component, add acceptable accessories, the medicine of any formulation of processing.Preferred formulation is an injection.
The application of black nightshade extract in the medicine that is preparing diseases such as prevention and treatment tumour, diabetes, asthma, heart disease as active component as third aspect present invention.
Above-mentioned black nightshade extract is following as the concrete medicinal usage of active component, but is not limited to following medicinal usage:
1, can in preparation prevention and treatment tumour medicine, use as active component with black nightshade extract.
2, can in preparation prevention and treatment diabetes medicament, use as active component with black nightshade extract.
3, can in preparation prevention and treatment asthma medicine, use as active component with black nightshade extract.
4, can in preparation prevention and treatment medicaments for coronary disease, use as active component with black nightshade extract.
Black nightshade extract of the present invention contains active component solasonine, solamargine and solasurine, and it has certain curative effect aspect diseases such as tumour, diabetes, asthma, coronary heart disease in prevention with treating.Preparation method of the present invention compared with prior art, this method technology is advanced, produces practically greatly, cost is relatively low.Organic solvent is mainly ethanol, and the soda acid after the use is discharging after treatment all, and environmental pollution is little.Extract obtained impurity is few, and active constituent content is high.
The specific embodiment
Below in conjunction with specific embodiment the present invention is done further explanation, but do not limit the present invention in any way.
Embodiment 1
The preparation of black nightshade extract:
(1) black nightshade herb 400g adds 90% ethanol 2000ml, refluxing extraction 3 times, each 1.5 hours;
(2) extract recovery ethanol gets the about 300ml of concentrate to there not being the alcohol flavor, petroleum ether extraction 3 times, and each consumption is 300ml;
(3) concentrate is processed into HD-8 strongly acidic cation-exchange (Shanghai Huazhen Science and Technology Co., Ltd.) the dress post absorption of H+ type with 400ml; It is closely colourless that water is eluted to outflow liquid successively; 40% ethanol 400ml wash-out; 90% ethanol 800ml wash-out contains ammoniacal liquor ethanol (90% ethanol: 25% ammoniacal liquor is 10: 1) 1200ml wash-out;
(4) collection contains ammoniacal liquor ethanol elution part, reclaims ethanol;
(5) concentrate 5000rpm is centrifugal 10 minutes, abandons supernatant;
(6) low amounts of water washing precipitation, centrifugal 10 minutes of 5000rpm so uses water washing 2 times, again with the small amount of acetone washing once, promptly gets black nightshade extract 0.17g, yield 0.04% behind the deposition drying under reduced pressure.
Wherein resin regeneration process is following: add the heat soaking resin with 2% sodium hydrate aqueous solution 800ml; The dress post, the sodium hydrate aqueous solution 800ml wash-out with 2%; Water is washed till outflow liquid and is neutral; Using 1N salt pickling resin is 2 to flowing out liquid pH value; Using deionized water to wash resin is 6 to flowing out liquid pH value, can drop into repeated use.
Embodiment 2
The preparation of black nightshade extract:
(1) Solanum nigrum fruit 1000g adds 90% ethanol 5000ml, refluxing extraction 3 times, each 1.5 hours;
(2) extract recovery ethanol gets the about 800ml of concentrate to there not being the alcohol flavor;
(3) concentrate is processed into HD-8 strongly acidic cation-exchange (Shanghai Huazhen Science and Technology Co., Ltd.) the dress post absorption of H+ type with 1000ml; It is closely colourless that water is eluted to outflow liquid successively; 40% ethanol 1000ml wash-out; 90% ethanol 2000ml wash-out contains ammoniacal liquor ethanol (90% ethanol: 25% ammoniacal liquor is 10: 1) 3000ml wash-out;
(4) collection contains ammoniacal liquor ethanol elution part, reclaims ethanol;
(5) concentrate 5000rpm is centrifugal 10 minutes, abandons supernatant;
(6) low amounts of water washing precipitation, centrifugal 10 minutes of 5000rpm so uses water washing 2 times, again with the small amount of acetone washing once, promptly gets black nightshade extract 1.5g, yield 0.15% behind the deposition drying under reduced pressure.
Wherein resin regeneration process is following: add the heat soaking resin with 2% sodium hydrate aqueous solution 2000ml; The dress post, the sodium hydrate aqueous solution 2000ml wash-out with 2%; Water is washed till outflow liquid and is neutral; Using 1N salt pickling resin is 2 to flowing out liquid pH value; Using deionized water to wash resin is 6 to flowing out liquid pH value, can drop into repeated use.
Embodiment 3
The preparation of black nightshade extract:
(1) black nightshade herb 400g adds 90% ethanol 2000ml, ultrasonic Extraction 3 times, each 1.5 hours;
(2) extract recovery ethanol gets the about 300ml of concentrate to there not being the alcohol flavor, petroleum ether extraction 3 times, and each consumption is 300ml;
(3) concentrate is processed into HD-8 strongly acidic cation-exchange (Shanghai Huazhen Science and Technology Co., Ltd.) the dress post absorption of H+ type with 400ml; It is closely colourless that water is eluted to outflow liquid successively; 40% ethanol 400ml wash-out; 90% ethanol 800ml wash-out contains 80% ethanol 1200ml wash-out of 0.1% NaOH;
(4) collection contains NaOH ethanol elution part, reclaims ethanol;
(5) concentrate 5000rpm is centrifugal 10 minutes, abandons supernatant;
(6) low amounts of water washing precipitation, centrifugal 10 minutes of 5000rpm.So with after the water washing 4 times, supernatant pH value is about 8.Promptly get black nightshade extract 0.13g, yield 0.03% after the deposition drying.
Wherein resin regeneration process is following: add the heat soaking resin with 2% sodium hydrate aqueous solution 800ml; The dress post, the sodium hydrate aqueous solution 800ml wash-out with 2%; Water is washed till outflow liquid and is neutral; Using 1N salt pickling resin is 2 to flowing out liquid pH value; Using deionized water to wash resin is 6 to flowing out liquid pH value, can drop into repeated use.
Embodiment 4
(LC-MS method) measured in alkaloidal discriminating in the black nightshade extract
Laboratory apparatus:
The LC-MS appearance, Agilent 1200 LC/MSD/VL
EISD, SoftA 300A
Enlightening horse C18 jewel post, 250 * 4.6mm
The HPLC condition:
Methyl alcohol: 0.2% acetate, gradient 0min, 5: 95; 10min, 5: 95; 15min, 90: 10; 25min, 100: 0.Flow velocity 0.8ml/min, 35 ℃ of column temperatures.
The EISD testing conditions:
DT＝70℃，SC＝35℃，GAS＝50psi
Experimental technique and result:
Get black nightshade extract 10mg, the accurate title, decide, put in the 25ml measuring bottle, and the small amount of methanol dissolving, methyl alcohol is diluted to scale, 0.45 μ m filtering with microporous membrane, 10 μ l sample introductions.The one group peak of retention time between 16～20 minutes is glycoalkaloid, and the peak area sum accounts for 85% of total peak area.HPLC-MS detects molecular ion peak 17.5min, 884 (solasonine, M+1); 17.8,868 (solamargine, M+1); 18.2,722 (solasurine, M+1).
Embodiment 5
The mensuration of alkaloid (thin layer chromatography scanning) in the black nightshade extract
Laboratory apparatus:
Tianjin, island CS-9310 type dual-wavelength lamellar scanning appearance
The TLC condition:
High-efficient silica gel G plate 10cm * 20cm; Solvent is a n-butanol: ammoniacal liquor (4: 1) upper strata liquid; The bismuth potassium iodide colour developing; λ S=468nm scanning.
Experimental technique and result:
Get black nightshade extract 10.05mg, the accurate title, decide, and puts in the 5ml measuring bottle small amount of methanol dissolving; Methyl alcohol is diluted to scale, shakes up, and gets 5 μ l point samples, launches; Colour developing, scanning, the area percentage of solasonine, solamargine and three points of solasurine is 40.5%, 25.4% and 34.1%.
Embodiment 6
The preparation of black nightshade extract injection
Get black nightshade extract 2000mg, add injection water 900ml, 1,2-propane diols 50ml, sodium chloride 9g with the hydrochloric acid adjust pH to 4.0 of 0.1N, adds the injection water to 1000ml, with 0.2 μ m filtering with microporous membrane, embedding, moist heat sterilization gets the black nightshade extract injection.
Embodiment 7
The black nightshade extract gastric infusion is to the experimental study of rat liver cancer H22 influence
Choose the female C57BL/6 mouse of 18～20g, get well-grown rat liver cancer H22 ascites, be diluted to 1～2 * 10 with physiological saline
7The cell suspension of individual/ml concentration, every the right armpit subcutaneous vaccination of mouse 0.2ml, random packet, several 10 of every treated animal, 15 of control groups, establish:
Blank group (coordinative solvent, 25ml/kg, ig * 7)
Syklofosfamid ampoule (30mg/kg, ip * 7)
Black nightshade extract (50mg/kg, ig * 7)
Black nightshade extract (100mg/kg, ig * 7)
Black nightshade extract (200mg/kg, ig * 7)
Black nightshade extract is made into suspension with 0.5%CMC after with several Tween-80 hydrotropies, and syklofosfamid ampoule is mixed with desired concn with physiological saline.
Administration is played next day in the inoculation back, and the administration volume is the 0.5ml/20g body weight, and per os was irritated stomach 7 days continuously.Inoculate back 10 days and take off neck execution animal, dissect and get the knurl piece, claim that knurl is heavy, calculate tumour inhibiting rate.
Result of the test is seen table 1, and black nightshade extract can obviously reduce rat liver cancer H22 tissue level 50,100, on the level of 200mg/kg during the per os gastric infusion.After the administration 7 days, each administration group is compared with control group, and knurl is heavy, and there were significant differences (P＜0.01).
Table 1. black nightshade extract gastric infusion is to the tumor-inhibiting action of rat liver cancer H22
Compare with control group:
*P＜0.05,
*P＜0.01.
Embodiment 8
The black nightshade extract gastric infusion is to the experimental study of Mice Bearing Lewis Lung Cancer influence
Choose the female C57BL/6 mouse of 18～20g, get well-grown Mice Bearing Lewis Lung Cancer knurl piece, be prepared into 1～2 * 10 with physiological saline homogenate method
7The cell suspension of individual/ml concentration, every the right armpit subcutaneous vaccination of mouse 0.2ml, random packet, several 6 of each treated animal, 12 of control groups, establish:
The blank group (coordinative solvent, 25ml/kg)
Syklofosfamid ampoule (30mg/kg, ip * 7)
Black nightshade extract (50mg/kg, ig * 10)
Black nightshade extract (100mg/kg, ig * l0)
Black nightshade extract (200mg/kg, ig * 10)
Black nightshade extract is made into suspension with 0.5%CMC after with several Tween-80 hydrotropies, and syklofosfamid ampoule is mixed with desired concn with physiological saline.
Inoculation plays administration next day, and the administration volume is the 0.5ml/20g body weight, and per os was irritated stomach 10 days continuously.Inoculate back 14 days and take off neck execution animal, dissect and get the knurl piece, claim that knurl is heavy, calculate tumour inhibiting rate.
Result of the test is seen table 2, and black nightshade extract can obviously reduce the Mice Bearing Lewis Lung Cancer tissue level 50,100, on the level of 200mg/kg during the per os gastric infusion.After the administration 10 days, each administration group is compared with control group, and knurl is heavy, and there were significant differences (P＜0.01).
Table 2. black nightshade extract gastric infusion is to the tumor-inhibiting action of Mice Bearing Lewis Lung Cancer
Compare with control group:
*P＜0.05,
*P＜0.01.
Embodiment 9
The experimental study that black nightshade extract is subcutaneous, intraperitoneal administration influences rat liver cancer H22
Choose the female C57BL/6 mouse of 18～20g, get well-grown rat liver cancer H22 ascites, be prepared into 1～2 * 10 with physiological saline homogenate method
7The cell suspension of individual/ml concentration, every the right armpit subcutaneous vaccination of mouse 0.2ml, random packet, several 10 of each treated animal, 15 of control groups, establish:
The blank group (coordinative solvent, 25ml/kg)
Syklofosfamid ampoule (30mg/kg, ip * 7)
Black nightshade extract (40mg/kg, sc * 10)
Black nightshade extract (40mg/kg, ip * 10)
Black nightshade extract is made into suspension with 0.5%CMC after with several Tween-80 hydrotropies, and syklofosfamid ampoule is mixed with desired concn with physiological saline.
Inoculation plays administration next day, and the administration volume is the 0.5ml/20g body weight, subcutaneous continuously, intraperitoneal administration 7 days.Inoculate back 10 days and take off neck execution animal, dissect and get the knurl piece, claim that knurl is heavy, calculate tumour inhibiting rate.
Result of the test is seen table 3, and black nightshade extract can obviously reduce rat liver cancer H22 tissue level when subcutaneous and intraperitoneal administration on the level of 40mg/kg.After the administration 7 days, black nightshade extract 40mg/kg subcutaneous administration group, intraperitoneal injection group are compared with control group, and knurl is heavy, and there were significant differences (P＜0.01).
Table 3. black nightshade extract is subcutaneous, intraperitoneal administration is to the tumor-inhibiting action of rat liver cancer H22
Compare with control group:
*P＜0.05,
*P＜0.01.
Embodiment 10
The experimental study that black nightshade extract is subcutaneous, intraperitoneal administration influences Mice Bearing Lewis Lung Cancer
Choose the male C57BL/6 mouse of 18～20g, get well-grown mice lung cancer knurl piece, be prepared into 1～2 * 10 with physiological saline homogenate method
7The cell suspension of individual/ml concentration, every the right armpit subcutaneous vaccination of mouse 0.2ml, random packet, several 10 of each treated animal, 15 of control groups, establish:
The blank group (coordinative solvent, 25ml/kg)
Syklofosfamid ampoule (30mg/kg, ip * 7)
Black nightshade extract (40mg/kg, sc * 10)
Black nightshade extract (40mg/kg, ip * 10)
Black nightshade extract is made into suspension with 0.5%CMC after with several Tween-80 hydrotropies, and syklofosfamid ampoule is mixed with desired concn with physiological saline.
Inoculation plays administration next day, and the administration volume is the 0.5ml/20g body weight, subcutaneous continuously, intraperitoneal administration 10 days.Inoculate back 14 days and take off neck execution animal, dissect and get the knurl piece, claim that knurl is heavy, calculate tumour inhibiting rate.
Result of the test is seen table 4, and black nightshade extract can obviously reduce the Mice Bearing Lewis Lung Cancer tissue level when subcutaneous and intraperitoneal administration on the level of 40mg/kg.After the administration 10 days, black nightshade extract 40mg/kg intraperitoneal injection group is compared with control group, and knurl is heavy, and there were significant differences (P＜0.01).
Table 4. black nightshade extract is subcutaneous, intraperitoneal administration is to the tumor-inhibiting action of Mice Bearing Lewis Lung Cancer
Compare with control group:
*P＜0.05,
*P＜0.01.
Embodiment 11
Black nightshade extract is to the influence of normal mouse postprandial blood sugar
Choose 18～20g male mice in kunming; Be divided into blank group (physiological saline), positive control group (glibenclamide 2.5mg/kg), administration group I (black nightshade extract 10mg/kg) and administration group II (black nightshade extract 20mg/kg) at random by body weight; Every group each 6, water is can't help in the 18h fasting before the test, behind the gastric infusion 1,2,4,8, the 10h tail vein blood; Behind the centrifugal separation plasma, measure glucose level with glucose oxidase-peroxidase (GOD-POD) method.
Result of the test is seen table 5, and black nightshade extract can obviously reduce the normal mouse level of postprandial blood sugar 10, on the level of 20mg/kg.Behind administration 8h, the 10h, the 20mg/kg dose groups is compared with control group, and there were significant differences for blood glucose value (P＜0.01).
Table 5. black nightshade extract is to the influence of normal mouse postprandial blood sugar
| Group | Dosage (mg/kg) | Blood sugar level (mg/dl) | |||||
| 0h | 1h | 2h | 4h | 8h | 10h | ||
| Blank | 2ml/kg | 98.11±5.25 | 98.77±5.76 | 97.07±6.22 | 94.20±5.02 | 90.47±4.82 | 91.44±5.02 |
| Glibenclamide | 2.5 | 97.54±6.21 | 97.29±6.34 | 88.94±5.73 | 83.99±3.94 | 70.04±3.21 ** | 56.84±3.00 ** |
| The black nightshade TA | 10 | 98.79±6.95 | 99.20±5.21 | 93.05±7.26 | 88.47±4.21 | 83.56±2.57 | 77.28±2.56 * |
| 20 | 99.64±6.28 | 98.49±6.32 | 89.53±4.77 | 84.55±4.50 | 80.03±2.12 ** | 69.14±3.11 ** | |
Compare with control group:
*P＜0.05,
*P＜0.01 (n=6).
Embodiment 12
Black nightshade extract is to the influence of tissue of experimental diabetic mice postprandial blood sugar
Choose 18～20g male mice in kunming; Water is can't help in the 24h fasting, presses 120mg/kg lumbar injection alloxan physiological salt liquid, feeding behind the 1h; Tail vein blood is measured blood sugar level behind the 48h, and the mouse that reaches more than the 200mg/100ml when blood glucose value is decided to be the diabetes model mouse.It is divided into blank group (physiological saline), positive control group (glibenclamide 2.5mg/kg), administration group I (black nightshade extract 10mg/kg) and administration group II (black nightshade extract 20mg/kg) at random by body weight; Every group each 6; Behind the gastric infusion 1,2,4,8, the 10h tail vein blood; Behind the centrifugal separation plasma, measure glucose level with glucose oxidase-peroxidase (GOD-POD) method.
Result of the test is seen table 6, and black nightshade extract can obviously reduce the tissue of experimental diabetic mice level of postprandial blood sugar 10, on the level of 20mg/kg.Behind administration 4h, 8h and the 10h, each dose groups is compared with control group, and there were significant differences for blood glucose value (P＜0.01).
Table 6. black nightshade extract is to the influence of tissue of experimental diabetic mice postprandial blood sugar
| Group | Dosage (mg/kg) | Blood sugar level (mg/dl) | |||||
| 0h | 1h | 2h | 4h | 8h | 10h | ||
| Blank | 2ml/kg | 274.11±10.44 | 278.19±10.20 | 288.41±9.73 | 299.10±10.02 | 505.21±11.82 | 320.85±5.02 |
| Glibenclamide | 2.5 | 269.48±11.22 | 261.33±12.54 | 214.85± 8.62 ** | 164.33± 9.03 ** | 119.53± 8.21 ** | 91.44±9.08 ** |
| The black nightshade TA | 10 | 285.02±12.75 | 281.73±10.02 | 273.99±7.06 | 220.49± 8.04 ** | 152.11± 8.57 ** | 127.28± 6.59 ** |
| 20 | 284.33±10.46 | 269.44±9.21 | 250.18±9.21 | 181.40± 7.67 ** | 139.40± 7.10 ** | 108.14± 5.71 ** | |
Compare with control group:
*P＜0.05,
*P＜0.01 (n=6).
Embodiment 13
Black nightshade extract is to the influence of cavy experimental asthma
Choose 200～250g healthy guinea pig and be divided into normal control group, asthmatic model group, administration group I (black nightshade extract 10mg/kg) and administration group II (black nightshade extract 20mg/kg) at random, every group each 6.Set up the asthmatic guinea pigs model with ovalbumin (OVA) lumbar injection sensitization with atomizing to suck to excite.Detect serum NO level, T-NOS, iNOS level.
Result of the test is seen table 7, and black nightshade extract can obviously reduce serum NO level, T-NOS and iNOS level 10, on the level of 20mg/kg, and relatively there were significant differences (P＜0.05) with model group.
Table 7. black nightshade extract is to the influence of cavy experimental asthma
| Group | Dosage (mg/kg) | NO(μmol/L) | T-NOS(U/ml) | iNOS(U/ml) |
| Normal control | 68.3±35.6 | 28.11±2.06 | 5.78±0.32 | |
| Asthmatic model | 150.44±49.65 | 43.96±3.22 | 10.28±1.99 | |
| Black nightshade extract | 10 | 84.22±35.74 * | 33.61±3.09 * | 7.59±1.92 * |
| 20 | 69.18±23.11 * | 31.28±1.50 * | 5.58±1.42 * |
Compare with model group:
*P＜0.05 (n=6).
Embodiment 14
Black nightshade extract is to the protective effect of myocardial ischemia-reperfusion injury
Adopt isolated rat perfusion heart (Langendorff heart) ischemia-reperfusion injury model; With the K-HShi buffer solution perfused hearts that contains black nightshade extract; Detect in the cardiac muscular tissue MDA content and to irritate in the 15min perfusate LDH more active, this two indexes can reflect and the closely-related oxygen radical level variation of myocardial damage indirectly.Chamber incidence of quivering of each group of record.The result that causes of perfusion is like table 8,9, shown in 10 again.
Table 8. black nightshade extract is to the quiver influence of incidence of isolated rat perfusion heart chamber
| Group | Number quivers in the chamber | The chamber incidence (%) of quivering |
| Negative control | 11 | 92.5 |
| Black nightshade extract (0.2g/L) | 5 | 46.7 |
| Black nightshade extract (2.0g/L) | 2 | 18.2 ** |
Annotate: compare with negative control group,
*P＜0.05,
*P＜0.01 (n=12).
Table 9. black nightshade extract is organized the influence of MDA content to isolated myocardium
| Group | MDA (mmol/g cardiac muscular tissue) |
| Negative control | 0.33±0.05 |
| Normal control | 0.16±0.02 ** |
| Black nightshade extract (0.2g/L) | 0.24±0.03 * |
| Black nightshade extract (2.0g/L) | 0.18±0.02 ** |
Annotate: compare with negative control group,
*P＜0.05,
*P＜0.01 (n=12).
Table 10. black nightshade extract extract is to irritate the active influence of LDH in the perfusate again
| Group | LDH(units/100ml) |
| Negative control | 144.2±11.7 |
| Black nightshade extract (0.2g/L) | 105.5±7.9 * |
| Black nightshade extract (2.0g/L) | 64.3±4.7 ** |
Annotate: compare with negative control group,
*P＜0.05,
*P＜0.01 (n=12).
More than show and described basic principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; The present invention is not restricted to the described embodiments; That describes in the foregoing description and the specification just explains principle of the present invention; The present invention also has various changes and modifications under the prerequisite that does not break away from spirit and scope of the invention, and these variations and improvement all fall in the scope of the invention that requires protection.The present invention requires protection domain to be defined by appending claims and equivalent thereof.
Claims (21)
1. the preparation method of a black nightshade extract is characterized in that, comprises the steps:
(1) black nightshade and fruit add alcohol extract, collect extract A;
(2) ethanol in the recovery extract gets concentrate B to there not being the alcohol flavor;
(3) concentrate B uses cationic exchange resin adsorption, and water, ethanol and contain alkali ethanol and carry out wash-out are successively collected and contained alkali ethanol elution portion C;
(4) contain alkali ethanol elution portion C, reclaim ethanol and get concentrate D;
(5) supernatant is abandoned in concentrate D centrifugation, gets sediment E;
(6) sediment E is washed with water to near-white and supernatant pH value less than 9, promptly gets black nightshade extract after the deposition drying.
2. the method for claim 1 is characterized in that, in above-mentioned steps (1), and at every turn make a living 2～8 times of volumes of dose of consumption of ethanol; The weight percent concentration of ethanol is 50%～90%.
3. the method for claim 1 is characterized in that, in above-mentioned steps (1), and at every turn make a living 5 times of volumes of dose of consumption of ethanol; The weight percent concentration of ethanol is 90%.
4. the method for claim 1 is characterized in that, in above-mentioned steps (1), adopts and refluxes or the ultrasonic power extraction, and extraction time is 2～5 times, each 1～3 hour.
5. the method for claim 1 is characterized in that, in above-mentioned steps (1), adopts and refluxes or the ultrasonic power extraction, and extraction time is 3 times, each 1.5 hours.
6. the method for claim 1 is characterized in that, when raw medicinal herbs is the black nightshade herb, in above-mentioned steps (2), increases the step of a pair of concentrate B with the petroleum ether extraction degreasing.
7. the method for claim 1 is characterized in that, when raw medicinal herbs is the black nightshade herb, in above-mentioned steps (2), increases the step of a pair of concentrate B with 3 degreasings of equal-volume petroleum ether extraction.
8. the method for claim 1 is characterized in that, in above-mentioned steps (3), and make a living 0.5～5 times of volume of dose of the consumption of said cationic ion-exchange resin.
9. the method for claim 1 is characterized in that, in above-mentioned steps (3), and make a living 1 times of volume of dose of the consumption of said cationic ion-exchange resin.
10. the method for claim 1 is characterized in that, in above-mentioned steps (3), the functional group of said cationic ion-exchange resin is a kind of among sulfonic group, pyrovinic acid base, phosphate, carboxyl and the phenolic hydroxyl group.
11. the method for claim 1 is characterized in that, in above-mentioned steps (3), the functional group of said cationic ion-exchange resin is a sulfonic group.
12. the method for claim 1; It is characterized in that; In above-mentioned steps (3); The elution process that adopts is closely colourless to flowing out liquid with washed resin for successively, and the weight percent concentration of 1～10 times of resin volume is 30%～90% ethanol elution, 0.5～10 times of resin volume contain the alkali ethanol elution.
13. the method for claim 1; It is characterized in that; In above-mentioned steps (3), the elution process of employing is closely colourless to flowing out liquid with washed resin for successively, and the weight percent concentration of 1～2 times of resin volume is 30%～60% ethanol elution; The weight percent concentration of 1～5 times of resin volume is 90% ethanol elution, 1～5 times of resin volume contain the alkali ethanol elution.
14. the method for claim 1; It is characterized in that; In above-mentioned steps (3), the elution process of employing is closely colourless to flowing out liquid with washed resin for successively, and the weight percent concentration of 1 times of resin volume is 40% ethanol elution; The weight percent concentration of 2 times of resin volumes is 90% ethanol elution, 3 times of resin volumes contain the alkali ethanol elution.
15., it is characterized in that the described alkali ethanol that contains is that weight percent concentration is the mixed solution of 50%～95% ethanol and alkali like claim 3 or 10 or 11 or 12 described methods, wherein alkali is a kind of in ammoniacal liquor, NaOH, sodium carbonate, the sodium acid carbonate.
16., it is characterized in that the described alkali ethanol that contains is that weight percent concentration is that 90% ethanol is the solution that 25% ammoniacal liquor mixed in 10: 1 by volume with weight percent concentration like claim 3 or 10 or 11 or 12 described methods.
17. the method for claim 1 is characterized in that, in above-mentioned steps (6) if in sediment E color darker, increase by a usefulness washing with acetone and be precipitated to subalbous step.
18. method as claimed in claim 3 is characterized in that, described cationic ion-exchange resin can be regenerated, and the method for its regeneration is: add the heat soaking resin with 2% sodium hydrate aqueous solution; The dress post is with 2% sodium hydrate aqueous solution 800ml wash-out; Water is washed till outflow liquid and is neutral; Using 1N salt pickling resin is 2 to flowing out liquid pH value; Using deionized water to wash resin is 6 to flowing out liquid pH value, can drop into repeated use.
19. the black nightshade extract that a preparation method as claimed in claim 1 prepares is as the application of active component in preparation prevention and treatment diabetes medicament.
20. the black nightshade extract that a preparation method as claimed in claim 1 prepares is as the application of active component in preparation prevention and treatment asthmatic medicament.
21. the black nightshade extract that a preparation method as claimed in claim 1 prepares is as the application of active component in the protection medicine of preparation myocardial ischemia-reperfusion injury.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100336197A CN101337000B (en) | 2008-02-15 | 2008-02-15 | Solanum nigrum extract, preparation method and pharmaceutical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100336197A CN101337000B (en) | 2008-02-15 | 2008-02-15 | Solanum nigrum extract, preparation method and pharmaceutical application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101337000A CN101337000A (en) | 2009-01-07 |
| CN101337000B true CN101337000B (en) | 2012-04-25 |
Family
ID=40211265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100336197A Active CN101337000B (en) | 2008-02-15 | 2008-02-15 | Solanum nigrum extract, preparation method and pharmaceutical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101337000B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI414304B (en) * | 2011-05-04 | 2013-11-11 | G & E Herbal Biotechnology Co Ltd | Treatment of wart with a water soluble extract from plant of solanum genus |
| TWI476012B (en) | 2011-05-12 | 2015-03-11 | G & E Herbal Biotechnology Co Ltd | Treatment and/or prevention of inflammation and cutaneous photodamage and photoprotection of the skin with a water soluble extract from plant of solanum genus |
| CN102872260A (en) * | 2011-06-10 | 2013-01-16 | 德英生物科技股份有限公司 | Use of water-soluble extracts of plants of the Solanum genus for the treatment and/or prevention of inflammation and photodamage of the skin and photoprotection of the skin |
| CN106577844B (en) * | 2016-11-15 | 2019-08-30 | 中国农业科学院麻类研究所 | Preparation for preventing and treating pepper blight, its preparation and application |
| CN106509579B (en) * | 2016-11-24 | 2017-06-30 | 张锦超 | A kind of preparation method of black nightshade fruit product |
| CN107260685B (en) * | 2017-06-02 | 2020-11-24 | 神威药业集团有限公司 | Preparation method of solanum nigrum fruit formula granules |
| CN108324798A (en) * | 2018-05-10 | 2018-07-27 | 李明慧 | A kind of converted products and purposes of S. photeinocarpum |
| CN111214581A (en) * | 2018-11-26 | 2020-06-02 | 天津中新药业集团股份有限公司研究院分公司 | Preparation method and application of solanum nigrum fruit total alkaloids |
| CN109674884A (en) * | 2019-02-01 | 2019-04-26 | 李明慧 | Black nightshade product and processing method and purposes |
| CN109620885A (en) * | 2019-02-02 | 2019-04-16 | 李明慧 | A kind of black nightshade converted products and application thereof |
| CN110501200B (en) * | 2019-09-23 | 2022-05-03 | 吉林师范大学 | Method for extracting and separating effective components of recyclable black nightshade |
| CN111493255A (en) * | 2020-04-15 | 2020-08-07 | 吉林创岐生态农业技术开发有限公司 | Solanum torvum solid beverage and application thereof |
| CN114767766A (en) * | 2022-04-13 | 2022-07-22 | 陕西海斯夫生物工程有限公司 | Extraction method of black nightshade fruit extract |
-
2008
- 2008-02-15 CN CN2008100336197A patent/CN101337000B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101337000A (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101337000B (en) | Solanum nigrum extract, preparation method and pharmaceutical application thereof | |
| CN101337001B (en) | Solanum xanthocarpum extract, preparation method and use thereof | |
| CN1754541A (en) | Steroid saponin pharmaceutical composition and its preparation method and uses | |
| CN103070912B (en) | Sophora flavescens totall flavone extract product, preparation method and quality detection method | |
| CN104910240A (en) | Bougainvillea glabra triterpenoid saponin, hpyerglycemic drugs with triterpenoid saponin as active component and preparation method and application thereof | |
| CN101972294A (en) | New usage of eucommia ulmoides chemical composition as vessel protective agent | |
| WO2004054596A1 (en) | A medicament containing epidemium extract for treatment of prostatic hyperplasia and prostatitis | |
| CN101972385A (en) | Method for preparing general flavone in star-of-Bethlehem and application thereof to antitumor, anti-inflammatory and analgesic medicines | |
| CN101862346A (en) | Hypoglycemic application of a kind of ginseng acidic polysaccharide | |
| CN101352468A (en) | New application of horned melon and its extract in the preparation of antitumor drugs | |
| CN101084979B (en) | Medicinal preparation for cancer auxiliary treatment and its preparation method | |
| CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
| CN103417634B (en) | A kind of Ramulus Mori active site and its preparation method and application | |
| CN109528782A (en) | Ginkgo biloba p.e has the application of the drug for the treatment of or health care as synergist in preparation to sleep disturbance disease | |
| CN1165545C (en) | Method for separating and extracting total flavone from goldenrain tree plant and its application | |
| CN100586420C (en) | Astragaloside injection and preparation method thereof | |
| CN110227080B (en) | Application of mannoglucuronosyl poly (oligo) saccharide and derivative thereof in preparing medicament for treating and/or preventing type 2 diabetes | |
| CN102670865A (en) | Process for extracting active ingredients of American eleutherine rhizome | |
| CN1434042A (en) | Cattail pollen extract and preparation process and use thereof | |
| CN108125995B (en) | A kind of ginkgo biloba flavonoid extract and its application | |
| CN106074788B (en) | A kind of total alkaloid extract of birchwood and its preparation method and application | |
| CN1994277A (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN100355424C (en) | Application of aralia extract and aralia saponin for treating diabetes in preparation of medicine for treating diabetes | |
| CN109432193B (en) | Pharmaceutical composition for treating cough and preparation method thereof | |
| CN102134207B (en) | Urea compound and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221026 Address after: 201499 5th floor, building 1, 1888 Wangyuan Road, Fengxian District, Shanghai Patentee after: Shanghai Shuofang Pharmaceutical Technology Co.,Ltd. Address before: Room 650-02, Building 2, No. 351, Guoshoujing Road, Zhangjiang Hi Tech Park, Shanghai, March 2012 Patentee before: Shanghai Haitian Medical Technology Development Co.,Ltd. |